Disc Medicine Files 8-K on Feb 26, 2024

TL;DR

**Disc Medicine just dropped an 8-K, signaling new material info, so keep an eye out for details!**

AI Summary

Disc Medicine, Inc. filed an 8-K on February 26, 2024, under Regulation FD Disclosure and Financial Statements and Exhibits. The filing indicates a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, with the earliest event reported also on February 26, 2024. The company, incorporated in Delaware with IRS Employer Identification No. 85-1612845, is headquartered at 321 Arsenal Street, Suite 101, Watertown, MA 02472.

Why It Matters

This filing signals that Disc Medicine, Inc. has disclosed material non-public information, which could impact investors' decisions and the company's stock price. It ensures transparency and compliance with SEC regulations.

Risk Assessment

Risk Level: low — The filing itself is a standard disclosure and does not inherently indicate a high risk, but the content of the disclosure could be significant.

Key Numbers

• 20240226 — Filing Date (Date the 8-K was filed and earliest event reported)
• 001-39438 — Commission File Number (SEC identification for the registrant)
• 85-1612845 — IRS Employer Identification No. (Tax identification for Disc Medicine, Inc.)
• (617) 674-9274 — Business Phone Number (Contact number for Disc Medicine, Inc.)

Key Players & Entities

• Disc Medicine, Inc. (company) — Registrant
• February 26, 2024 (date) — Date of earliest event reported and filing date
• Delaware (company) — State of incorporation
• 85-1612845 (dollar_amount) — IRS Employer Identification No.
• 321 Arsenal Street, Suite 101, Watertown, MA 02472 (company) — Address of principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share IRON The Nasdaq Global Ma

Filing Documents

• d794509d8k.htm (8-K) — 24KB
• d794509dex991.htm (EX-99.1) — 12KB
• g794509g0223233412304.jpg (GRAPHIC) — 4KB
• 0001193125-24-045464.txt ( ) — 169KB
• iron-20240226.xsd (EX-101.SCH) — 3KB
• iron-20240226_lab.xml (EX-101.LAB) — 18KB
• iron-20240226_pre.xml (EX-101.PRE) — 11KB
• d794509d8k_htm.xml (XML) — 4KB

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 DISC MEDICINE, INC. (Exact name of registrant as specified in its charter) Delaware 001-39438 85-1612845 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 321 Arsenal Street , Suite 101 , Watertown , MA 02472 02472 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (617) 674-9274 N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.0001 per share IRON The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item7.01 Regulation FD Disclosure. On February 26, 2024, Disc Medicine, Inc. (the "Company") issued a press release announcing Pamela Stephenson's appointment as Chief Commercial Officer and the inducement grant material to Ms. Stephenson's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such filing. The Company undertakes no obligation to update, supplement or amend the material attached hereto as Exhibit 99.1. Item9.01. Exhibits. (d) Exhibits 99.1 Press release issued by Disc Medicine, Inc. on February 26, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DISC MEDICINE, INC. Date: February 26, 2024 By: /s/ John Quisel Name: John Quisel, J.D. Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR